Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2022-02-18
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 111); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-23 (study day 204); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 703); relationship: not assessed
severe
assessed
2026-08-18
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-05-14 (study day 803); relationship: N
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: UNKNOWN; onset 2024-08-09 (study day 890); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.